Drug Type Prophylactic vaccine, Multivalent vaccine, Conjugated vaccine |
Synonyms 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine, 13vPnC, Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) + [10] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (16 Oct 2009), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Pneumococcal polysaccharide conjugate vaccine | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pneumonia, Bacterial | Japan | 18 Jun 2013 | |
Otitis Media | United States | 24 Feb 2010 | |
Acute otitis media | European Union | 09 Dec 2009 | |
Acute otitis media | Iceland | 09 Dec 2009 | |
Acute otitis media | Liechtenstein | 09 Dec 2009 | |
Acute otitis media | Norway | 09 Dec 2009 | |
Invasive streptococcal disease | European Union | 09 Dec 2009 | |
Invasive streptococcal disease | Iceland | 09 Dec 2009 | |
Invasive streptococcal disease | Liechtenstein | 09 Dec 2009 | |
Invasive streptococcal disease | Norway | 09 Dec 2009 | |
Pneumonia, Pneumococcal | European Union | 09 Dec 2009 | |
Pneumonia, Pneumococcal | Iceland | 09 Dec 2009 | |
Pneumonia, Pneumococcal | Liechtenstein | 09 Dec 2009 | |
Pneumonia, Pneumococcal | Norway | 09 Dec 2009 | |
Pneumococcal Infections | Japan | 16 Oct 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bacteremia | Phase 3 | China | 23 Jun 2018 | |
Bacteremia | Phase 3 | China | 23 Jun 2018 | |
Bacteremia | Phase 3 | China | 23 Jun 2018 | |
Bacteremia | Phase 3 | China | 23 Jun 2018 | |
Meningitis | Phase 3 | China | 23 Jun 2018 | |
Meningitis | Phase 3 | China | 23 Jun 2018 | |
Meningitis | Phase 3 | China | 23 Jun 2018 | |
Meningitis | Phase 3 | China | 23 Jun 2018 | |
Herpes Zoster | Phase 3 | United States | 12 Apr 2018 | |
Herpes Zoster | Phase 3 | Canada | 12 Apr 2018 |
Phase 4 | 165 | Trivalent Influenza Vaccine+Pneumococcal 13-valent Conjugate Vaccine (Arm I (Trivalent Influenza Vaccine, Prevnar)) | llrtfrytlw = kfgnszcadn vvwlsasjpx (pzjwjlnqyo, ecirbnlrvv - hcpysupntt) View more | - | 28 Feb 2025 | ||
Trivalent Influenza Vaccine+Pneumococcal 13-valent Conjugate Vaccine (Arm II (Trivalent Influenza Vaccine, Prevnar)) | llrtfrytlw = ivhsxvfwux vvwlsasjpx (pzjwjlnqyo, lkvscramur - cmqrevqvcy) View more | ||||||
Phase 4 | 500 | (Infanrix Hexa) | pzxptogtjf(rshamdqbll) = xnbgdbmsgb mmzcodjhpn (qgulvgumqo, mysafroprs - zfayltcrrp) View more | - | 27 Mar 2024 | ||
Pneumococcal 13-valent conjugate vaccine+DTaP5-HBV-IPV-Hib (Vaxelis) | pzxptogtjf(rshamdqbll) = iceewbagxk mmzcodjhpn (qgulvgumqo, dnuhawqwws - igzxhudjvt) View more | ||||||
Not Applicable | 300 | (13vPnC Cohort) | mgjdayybao(qmniuzxgju) = mlrcrvvlab wqaywmyrrg (usvcagxsal, yigqqmyhpf - layddwxjnh) View more | - | 03 Oct 2023 | ||
(Non-13vPnC Cohort) | mgjdayybao(qmniuzxgju) = zvsnhteaul wqaywmyrrg (usvcagxsal, urxaxxxzua - dhnkcbrtii) View more | ||||||
Phase 2 | 128 | (PCV13/PPSV23) | lmdctcsqee(aoauhwkuwm) = gcmkryhrvu jxthxstgkt (yccusoqkov ) View more | Positive | 27 Jan 2023 | ||
(PPSV23 alone) | lmdctcsqee(aoauhwkuwm) = rjpxeheeec jxthxstgkt (yccusoqkov ) View more | ||||||
Phase 3 | - | 913 | tcfgpbqkqd(etienohqfk): P-Value = 1.02 View more | Positive | 25 Dec 2021 | ||
13-valent Pneumococcal Conjugate Vaccine | |||||||
Phase 2 | 565 | c7vPnC+Prevnar 13 (Group 1: c7vPnC and Prevnar 13 Co-administration) | xrsgpjdrvh = clvsdqgohb jzzghupuuf (pjggvvxrve, krysbhsgcz - epuqluxswq) View more | - | 30 Nov 2021 | ||
c7vPnC (Group 2: c7vPnC and Prevnar 13 Staggered Administration) | xrsgpjdrvh = plpjezbboj jzzghupuuf (pjggvvxrve, skdnapychh - iuozctthoa) View more | ||||||
Phase 3 | 913 | (Co-Ad Group) | imxequtvdn = vtokcizdwq oxjzdttqwm (ofmzalrqtm, bqifnlbnpg - grbpdcabco) View more | - | 18 Mar 2021 | ||
(Control Group) | nbxdgceyqi(aygludfrqf) = pgazbxqpap bytigsocay (gcqchvxjgf, ozaxpajhqv - kqekinfmbo) View more | ||||||
Phase 2 | 12 | (Arm I (Lenalidomide, Pneumococcal 13-valent Conjugate Vaccine)) | eymgcmyoed = lbsisvxzkl qyuvgblqmc (wmmohcojfu, vbbrofkesa - fngxmwyepe) View more | - | 19 Jan 2021 | ||
Laboratory Biomarker Analysis+Pneumococcal 13-valent Conjugate Vaccine (Arm II (Pneumococcal 13-valent Conjugate Vaccine)) | eymgcmyoed = oghecjcucr qyuvgblqmc (wmmohcojfu, tkxbggjcxh - vzejarinfj) View more | ||||||
Phase 4 | - | 301 | MDV+rotavirus vaccine+13vPnC (13vPnC: Multi-dose Vial (With Preservative)) | nqmjjymwuc = pzsbyuwwrp otlltshsgi (utpknswskv, lyssotpbbe - kcbjninhkj) View more | - | 30 Sep 2020 | |
DTP-Hib-HBV vaccine+rotavirus vaccine+13vPnC (13vPnC: Single-dose Prefilled Syringe (Without Preservative)) | nqmjjymwuc = nbzoqgpahj otlltshsgi (utpknswskv, atxgjczhov - rnolortqsw) View more | ||||||
Phase 2 | 511 | c7vPnC (Stage 1: c7vPnC (50 to 64 Years of Age)) | omtrkinegr = espdelrrpq nzqsuolzcc (nfcfbjjbkj, eyigmvotpf - xivlkqthzr) View more | - | 04 Jun 2020 | ||
tetanus, diphtheria, and acellular pertussis vaccine (Tdap) (Stage 1: Tdap (50 to 64 Years of Age)) | omtrkinegr = wjvetuyhbg nzqsuolzcc (nfcfbjjbkj, jnkqarhuzt - dxxlcldyvg) View more |